Development of sulforaphane-encapsulated microspheres for cancer epigenetic therapy

Area of Science:

• Oncology
• Epigenetics
• Drug Delivery Systems

Background:

• Conventional chemotherapy causes damage to healthy cells, necessitating novel anticancer agents with alternative mechanisms of action.
• Epigenetic therapy, targeting aberrant epigenetic modifications, offers a promising approach to cancer treatment.
• Histone deacetylase inhibitors, such as sulforaphane, are being investigated for their anticancer properties.

Purpose of the Study:

• To explore the potential of sulforaphane as an epigenetic therapy for cancer.
• To investigate the efficacy of polymeric drug delivery systems for sulforaphane to enhance therapeutic outcomes and minimize side effects.

Main Methods:

• In vitro studies using B16 and S91 melanoma cells to assess sulforaphane's effect on cancer cell growth and proliferation.
• Development of albumin microspheres encapsulating R,S-sulforaphane via spray drying.
• Characterization of microspheres (morphology, size, zeta potential) and evaluation of their efficacy in vitro (melanoma cells) and in vivo (melanoma tumor-bearing C57BL/6 mice).

Main Results:

• Sulforaphane inhibited the growth and proliferation of melanoma cells by downregulating deacetylation enzymes.
• Albumin microspheres effectively encapsulated sulforaphane.
• The albumin-based polymeric delivery system demonstrated efficacy in both cell culture and in vivo models, enhancing sulforaphane's therapeutic effect and anticancer activity.

Conclusions:

• Sulforaphane exhibits significant potential as an epigenetic agent for cancer therapy.
• Albumin microspheres represent a viable and effective drug delivery system for sulforaphane, improving its therapeutic index.
• This combined approach holds promise for enhanced anticancer treatment strategies.